Pharmacorp Rx Inc. (PCRX)
TSXV
0.4100
0.00 (0.00%)
Closed
Oct 9, 2026
Day's Range
0.41000.4100
52 wk Range
0.39000.5800
Financial Statements - PCRX - Pharmacorp Rx Inc.
Revenue
20.89M▲ 260.6%
Net Income
-1.42M▼ 35.3%Net Margin -6.8%
EBITDA
204.07K▲ 124.4%
Free Cash Flow
-171.23K▼ 245.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Sales | 20.89M | 5.79M | 0 | 0 |
| Cost of Goods | 12.59M | 3.61M | - | - |
| Gross Profit | 8.29M | 2.18M | - | - |
 Operating Expense | - | - | - | - |
| Operating Income | -1.23M | -1.58M | -577.96K | -563.17K |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | 207.61K | 82.13K | - | - |
| Pre Tax Income | -835.80K | -1.15M | -470.42K | -517.08K |
| Income Tax | 586.25K | -106.45K | - | - |
| Net Income | -1.42M | -1.05M | -470.42K | -517.08K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 |
| Basic Shares Outstanding | 125.13M | 81.72M | 40.22M | 32.54M |
| Diluted Shares Outstanding | 125.13M | 81.72M | 40.22M | 32.54M |
| Ebit | -736.12K | -1.12M | -577.96K | -563.17K |
| Ebitda | 204.07K | -835.07K | -577.96K | -563.17K |
| Net Income Continuous Operations | -1.42M | -1.05M | -470.42K | -517.08K |
| Minority Interests | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
